Hormone Therapy: Menopausal Hormone Therapy.
Journal
FP essentials
ISSN: 2159-3000
Titre abrégé: FP Essent
Pays: United States
ID NLM: 101578821
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
medline:
23
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
ppublish
Résumé
The marked decrease in estrogen levels in menopausal women can cause bothersome symptoms that affect daily life. More than 75% of women experience menopausal symptoms, which can include vaginal dryness, itching, discharge, dyspareunia, mood changes, hot flushes, and night sweats. Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms. Benefits include decreased risk of osteoporotic fractures and vaginal atrophy, improved glycemic control, and decreased vasomotor symptoms. However, recent research on risks associated with MHT has shown increased risk of venous thromboembolism and breast cancer. MHT typically is an option for patients younger than 60 years or within 10 years of menopause onset with bothersome vasomotor symptoms. The decision to start MHT should be made on an individual basis after a thorough evaluation and counseling. Oral, intramuscular, transdermal, and intravaginal formulations are available. The goal of therapy is use of the lowest dose for the shortest time that effectively manages symptoms. The patient and physician should regularly assess the risks and benefits associated with MHT and ensure that the benefits of its use continue to outweigh the risks.
Substances chimiques
Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15-21Informations de copyright
Written permission from the American Academy of Family Physicians is required for reproduction of this material in whole or in part in any form or medium.